Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation approaches. Few biological factors at diagnosi...
Guardado en:
Autores principales: | Natalia Estrada, Blanca Xicoy, Fabian Beier, Olga Garcia, Cristian Morales, Concepción Boqué, Miguel Sagüés, Mónica S. Ventura Ferreira, Rolando Vallansot, Sílvia Marcé, Marta Cabezón, Tim H. Brümmendorf, Lurdes Zamora |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wolters Kluwer
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eed0d7528f1d408cb71f85ec9f094861 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
por: Waclaw J, et al.
Publicado: (2015) -
Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
por: Shoumariyeh K, et al.
Publicado: (2014) -
GENERIC IMATINIB VS GLEEVEC
por: Katia Borgia Barbosa Pagnano
Publicado: (2021) -
NEW ADVANCES IN PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Özlem Tüfekçi
Publicado: (2021) -
EXPERIENCE OF GLASDEGIB IN PATIENTS WITH ELDERLY ACUTE MYELOID LEUKEMIA
por: Nanişe Gizem FENER, et al.
Publicado: (2021)